1. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-1413.
2. Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 2006;12:559-566.
3. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 1993;18:75-113.
4. Heidbreder C. Novel pharmacotherapeutic targets for the management of drug addiction. Eur J Pharmacol 2005;526:101-112.
5. Wise RA. Action of drugs of abuse on brain reward systems. Pharmacol Biochem Behav 1980;13:Suppl 1. 213-223.
6. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005;162:1414-1422.
7. Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR. Compulsive drug-seeking behavior and relapse: neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 2001;937:1-26.
9. Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol 2009;32:269-276.
11. Busto U, Sellers EM. Pharmacokinetic determinants of drug abuse and dependence: a conceptual perspective. Clin Pharmacokinet 1986;11:144-153.
12. Sakol MS, Stark C, Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow: an increase. Br J Addict 1989;84:439-441.
13. Jones RT. Psychopharmacology of cocaine. In: Washton AM, Gold MS, editor. Cocaine: a clinician's handbook. New York: Guildford Press; 1987. p. 55-72.
14. Brosen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-239.
15. Quinn DI, Wodak A, Day RO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet 1997;33:344-400.
17. Cook CE. Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine. NIDA Res Monogr 1991;115:6-23.
18. Nilsson MI, Meresaar U, Anggard E. Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand Suppl 1982;74:66-69.
19. Harding-Pink D. Methadone: one person's maintenance dose is another's poison. Lancet 1993;341:665-666.
20. Kleber HD, Kosten TR, Gaspari J, Topazian M. Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry 1985;20:66-72.
22. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990;47:525-534.
23. Jarrott B, Conway EL, Maccarrone C, Lewis SJ. Clonidine: understanding its disposition, sites and mechanism of action. Clin Exp Pharmacol Physiol 1987;14:471-479.
24. Washton AM, Resnick RB, Geyer G. Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects. J Clin Psychiatry 1983;44:335-337.
25. Foltin RW, Fischman MW. Self-administration of cocaine by humans: choice between smoked and intravenous cocaine. J Pharmacol Exp Ther 1992;261:841-849.
26. Morishima HO, Whittington RA. Species-, gender-, and pregnancy-related differences in the pharmacokinetics and pharmacodynamics of cocaine. NIDA Res Monogr 1995;158:2-21.
27. Anggård E, Gunne LM, Jönsson LE. Relationships between pharmacokinetic and clinical parameters in chronic amphetamine abuse. Acta Pharmacol Toxicol (Copenh) 1970;28:92.
28. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci 1992;648:371-382.
29. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl) 1981;74:208-212.
30. Griffiths RR, Ator NA, Lukas SE, Lamb RJ, Brady JV. Benzodiazepines: drug discrimination and physiological dependence. NIDA Res Monogr 1984;49:163-164.